Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 37 Neoplasm Metastasis 6 Neoplasms by Site 2 Neoplasms 2 Hereditary Sensory and Autonomic Neuropathies 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Diseases 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Locoregional Recurrence 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Liposarcoma 1 Leiomyosarcoma 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 HER2 Negative Breast Cancer Not Immediately Operated 1 HER2 Negative Breast Cancer 1 Glioma 1 Glioblastoma 1

Interventions

Letrozole 4 Fulvestrant 4 trastuzumab deruxtecan 2 toripalimab 2 elacestrant 2 Injections 2 Anastrozole 2 AZD9833 2 ribociclib 1 palbociclib 1 exemestane 1 disitamab vedotin 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 Ritonavir 1 RAD1901 1 Paclitaxel 1 Lead 1 Itraconazole 1 Goserelin 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Alpelisib 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × ribociclib × 90 days × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡